208 related articles for article (PubMed ID: 32184607)
1. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
Li X; Ye C; Zhang W; Jia M; Wang G
CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Hargarter L
Neuropsychiatr Dis Treat; 2019; 15():587-602. PubMed ID: 30863080
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
6. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
Nash AI; Turkoz I; Savitz AJ; Mathews M; Kim E
Neuropsychiatr Dis Treat; 2019; 15():731-737. PubMed ID: 30962688
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
Brown B; Turkoz I; Mancevski B; Mathews M
Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
[TBL] [Abstract][Full Text] [Related]
11. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
13. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
[TBL] [Abstract][Full Text] [Related]
14. Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
O'Donnell A; Rao S; Turkoz I; Gopal S; Kim E
Neuropsychiatr Dis Treat; 2021; 17():1-9. PubMed ID: 33442251
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
[TBL] [Abstract][Full Text] [Related]
17. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Hough D; Mathews M
Int Clin Psychopharmacol; 2017 Nov; 32(6):329-336. PubMed ID: 28806194
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
Garcia-Portilla MP; Llorca PM; Maina G; Bozikas VP; Devrimci-Ozguven H; Kim SW; Bergmans P; Usankova I; Pungor K
Ther Adv Psychopharmacol; 2020; 10():2045125320926347. PubMed ID: 32518617
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
Mathews M; Gopal S; Singh A; Nuamah I; Pungor K; Tan W; Soares B; Kim E; Savitz AJ
Neuropsychiatr Dis Treat; 2020; 16():1533-1542. PubMed ID: 32606705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
